In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose-dependently prolongs heparinase-modified tissue factor-activated thromboelastography parameters and prothrombinase-induced clotting time

Veterinary Clinical Pathology

Volumn 37, Issue 4, 2008, Pages 363-372

  Jessen, Lisbeth R ^a   Wiinberg, Bo ^a   Jensen, Asger L ^a   Kjelgaard Hansen, Mads ^a   Jensen, Kate H ^a   Pedersen, Lotte B ^a   Kristensen, Annemarie T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anti xa; Assay; Dog; Low molecular weight heparin; Thromboelastography

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; HEPARIN LYASE; KAOLIN; THROMBOPLASTIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD CLOTTING; DOG; DOSE RESPONSE; DRUG EFFECT; FEMALE; MALE; METABOLISM; THROMBOELASTOGRAPHY;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DALTEPARIN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN LYASE; KAOLIN; MALE; THROMBELASTOGRAPHY; THROMBOPLASTIN;

CANIS FAMILIARIS;

EID: 58049150413     PISSN: 02756382     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-165X.2008.00068.x     Document Type: Article

References (29)

1. Koller M, Schoch U, Buchmann P, et al. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemost. 1986;56:243-246.
2. Gomez-Outes A, Lecumberri R, Lafuente-Guijosa A, et al. Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis. J Thromb Haemost. 2004;2:1581-1587.
3. Luomanmaki K, Grankvist S, Hallert C, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med. 1996;240:85-92.
4. Grebe S, Jacobs C, Kietzmann M, Mischke R. [Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. Berl Munch Tierarztl Wochenschr. 2000;113:103-107.
5. Mischke R, Fehr M, Nolte I. Efficacy of low molecular weight heparin in a canine model of thromboplastin-induced acute disseminated intravascular coagulation. Res Vet Sci. 2005;79:69-76.
6. Morris TA, Marsh JJ, Konopka R, Pedersen CA, Chiles PG. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism. Thromb Res. 2000;100:185-194.
7. Szucs G, Miko I, Ajzner E, et al. Efficacy of prevention of thromboembolic complications with LMW-heparin in experiment. Acta Chir Hung. 1997;36:356-358.
8. Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis. 1993;23(Suppl l):89-98.
9. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol. 1999;104:230-240.
10. Hakki SI, Fareed J, Hoppensteadt DA, et al. Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery. Clin Appl Thromb Hemost. 2001;7:65-71.
11. Wiinberg B, Jensen AL, Rojkjaer R, et al. Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs. Vet Clin Pathol. 2005;34:389-393.
12. Srinivasa V, Gilbertson LI, Bhavani-Shankar K. Thromboelastography: where is it and where is it heading? Int Anesthesiol Clin. 2001:39:35-49.
13. Harding SA, Mallett SV, Peachey TD, Cox DJ. Use of heparinase modified thrombelastography in liver transplantation. Br J Anaesth. 1997;78:175-179.
14. Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth. 2001;86:575-578.
15. Shore-Lesserson L. Evidence based coagulation monitors: heparin monitoring, thromboelastography, and platelet function. Semin Cardiothorac Vasc Anesth. 2005;9:41-52.
16. Shinoda T, Arakura H, Katakura M, Shirota T, Nakagawa S. Usefulness of thromboelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis. Artificial Organs. 1999;14:413-415.
17. Fenyvesi T, Jorg I, Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb. 2002;32:174-179.
18. Wiinberg B, Jensen AL, Kjelgaard-Hansen M, et al. Study on biological variation of haemostatic parameters in clinically healthy dogs. Vet J. 2007;174:62-68.
19. Mischke R, Grebe S. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin. Res Vet Sci. 2000;69:241-247.
20. Mischke R, Grebe S, Jacobs C, Kietzmann M. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. Am J Vet Res. 2001;62:595-598.
21. Zmuda K, Neofotistos D, Ts'ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol. 2000;113:725-731.
22. Gerotziafas GT, Chakroun T, Samama MM, Elalamy I. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thromb Haemost. 2004;92:1296-1302.
23. Jessen LR, Wiinberg B, Kjelgaard-Hansen M, Kristensen AT. Dalteparin causes significant dose
24. related changes in tissue factor and kaolin activated whole blood thromboelastography (TEG) parameters [abstract]. J Vet Intern Med. 2006;20:714.
25. White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol. 2003;121:12-20.
26. Houbouyan L, Boutiere B, Contant G, et al. Validation protocol of analytical hemostasis systems: measurement of anti-Xa activity of low-molecular-weight heparins. Clin Chem. 1996;42:1223-1230.
27. Desjardins L, Bara L, Boutitie F, et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med. 2004;128:519-526.
28. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost. 2002;87:163-164.
29. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78:2337-2343.